Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient preference crossover study of subcutaneous versus intravenous trastuzumab in HER2-positive early breast cancer
2010-024099-25Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by Roche. Started Jul 2011; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-024099-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024099-25.